阿替普酶治疗发病4.5至24小时急性缺血性卒中:HOPE随机临床试验
HOPE试验在中国26家卒中中心纳入372例经灌注影像证实存在可挽救脑组织、且初始未计划血管内取栓的急性缺血性卒中患者,随机接受阿替普酶0.9 mg/kg(最大90 mg)静脉溶栓或标准药物治疗。结果显示阿替普酶组90天功能独立比例高于对照组,但症状性颅内出血发生率更高,两组死亡率无显著差异。
要点
- 发病4.5至24小时、灌注影像显示可挽救脑组织的急性缺血性卒中患者,阿替普酶组90天功能独立(mRS 0-1)40% vs 对照组26%。
- 阿替普酶组症状性颅内出血3.8% vs 标准治疗0.51%,调整风险比7.34(95%CI 1.54-34.84),P=.01。
- 两组90天全因死亡率均为11%,调整风险比0.91(95%CI 0.52-1.62),P=.76。
核心结论
- 对于经灌注影像证实存在可挽救脑组织、且初始未接受取栓的急性缺血性卒中患者,发病4.5至24小时后静脉给予阿替普酶可提供功能获益,尽管症状性颅内出血增加。
研究设计与样本
- 随机、开放标签、盲法终点试验,在中国26家卒中中心开展。
- 共纳入372例急性缺血性卒中患者,入组时间为2021年6月21日至2024年6月30日,最终随访至2024年10月2日。
- 纳入标准包括卒中发病(若发病时间未知,则取最后已知正常与症状识别之间的中点)至就诊4.5至24小时,且初始未计划血管内取栓。
- 患者按1:1随机接受静脉阿替普酶0.9 mg/kg(最大剂量90 mg,n=186)或标准药物治疗(n=186)。
- 数据析分析时间为2024年12月至2025年2月。
主要发现
- 372例患者中位年龄72岁(IQR 64-80),女性160例(43%),全部完成试验。
- 主要疗效终点90天功能独立(mRS 0-1)在阿替普酶组186例中发生75例(40%),对照组186例中发生49例(26%);调整风险比1.52(95%CI 1.14-2.02),P=.004;未调整风险差13.98%(95%CI 4.50%-23.45%)。
- 症状性颅内出血发生率阿替普酶组3.8% vs 标准治疗组0.51%;调整风险比7.34(95%CI 1.54-34.84),P=.01;未调整风险差3.23%(95%CI 0.28%-6.19%)。
- 90天全因死亡率两组均为11%;调整风险比0.91(95%CI 0.52-1.62),P=.76;未调整风险差0%(95%CI -6.30%至6.30%)。
关键数值与推荐
- 主要疗效终点为90天功能独立,定义为改良Rankin量表评分0至1分。
- 安全性终点包括36小时内症状性颅内出血和90天内全因死亡率。
- 阿替普酶用法为静脉0.9 mg/kg,最大剂量90 mg。
临床怎么用
- 对于经灌注影像筛选存在可挽救脑组织、且初始未计划取栓的急性缺血性卒中患者,发病4.5至24小时静脉阿替普酶可提供功能获益,但症状性颅内出血风险增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The safety and efficacy of intravenous thrombolytics beyond 4.5 hours after ischemic stroke onset remain inadequately studied. OBJECTIVE: To evaluate the safety and efficacy of intravenous alteplase administered 4.5 to 24 hours after stroke onset in patients with salvageable brain tissue, regardless of the presence of large vessel occlusion. DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label, blinded end-point trial was conducted at 26 stroke centers across China. A total of 372 patients with acute ischemic stroke and salvageable brain tissue identified by perfusion imaging were enrolled between June 21, 2021, and June 30, 2024 (final follow-up October 2, 2024). Eligibility criteria included stroke onset (or the midpoint between last known well and symptom recognition if onset was unknown) of 4.5 to 24 hours prior to presentation, and no initial plan for endovascular thrombectomy. Data were analyzed from December 2024 to February 2025. INTERVENTIONS: Patients were randomly assigned (1:1) using a minimization algorithm to receive intravenous alteplase (0.9 mg/kg; maximum dose, 90 mg; n = 186) or standard medical treatment (n = 186). MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was functional independence, defined as a modified Rankin Scale score of 0 to 1 at 90 days. Safety outcomes included symptomatic intracranial hemorrhage within 36 hours and all-cause mortality within 90 days. RESULTS: Among 372 patients who were enrolled (median [IQR] age, 72 [64-80] years; 160 [43%] women), all completed the trial. The primary outcome occurred in 75 of 186 patients (40%) in the alteplase group and 49 of 186 (26%) in the control group (adjusted risk ratio, 1.52 [95% CI, 1.14-2.02]; P = .004; unadjusted risk difference, 13.98% [95% CI, 4.50%-23.45%]). The incidence of symptomatic intracranial hemorrhage was higher with alteplase at 3.8% compared with 0.51% with standard treatment (adjusted risk ratio, 7.34 [95% CI, 1.54-34.84]; P = .01; unadjusted risk difference, 3.23% [0.28%-6.19%]), and mortality was 11% in both groups (adjusted risk ratio, 0.91 [95% CI, 0.52-1.62]; P = .76; unadjusted risk difference, 0% [95% CI, -6.30% to 6.30%]). CONCLUSIONS AND RELEVANCE: In patients with acute ischemic stroke with salvageable brain tissue identified by perfusion imaging who did not initially receive thrombectomy, intravenous alteplase administered 4.5 to 24 hours after onset provided functional benefit, despite an increase in symptomatic intracranial hemorrhage. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04879615.
引用
- Zhou Y, He Y, Campbell BCV, et al. Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial. JAMA. 2025. PMID: 40773205. doi:10.1001/jama.2025.12063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。